KRINGLE PHARMA
Kringle Pharma, Inc., a biopharmaceutical company, develops pharmaceutical products based on its research on hepatocyte growth factor (HGF) and NK4. Its HGF has the regenerative healing ability in regard to liver cells, as well as various cells and organs; and NK4 is a bi-functional molecule, which inhibits the invasion and metastasis of tumor cells as an HGF-antagonist, as well as possesses antiangiogenic activity. The company’s pipeline includes recombinant human HGF for the treatment of acute renal failure, skin ulcers, and CNS diseases; and recombinant human NK4 and NK4 gene drugs for cancer therapy. Kringle Pharma, Inc. was founded in 2001 and is based in Toyonaka, Japan.
KRINGLE PHARMA
Industry:
Biotechnology Medical Nursing And Residential Care Pharmaceutical
Founded:
2001-12-21
Address:
Toyonaka, Osaka, Japan
Country:
Japan
Website Url:
http://www.kringle-pharma.com
Total Employee:
11+
Status:
Active
Contact:
81 6 6831 3330
Email Addresses:
[email protected]
Total Funding:
36.19 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Ascentage Pharma
Ascentage is a clinical-stage biopharmaceutical company that develops drugs for the treatment of cancer.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
IntraBio
IntraBio is a biopharmaceutical company.
Current Employees Featured
Founder
Investors List
Maruishi Pharmaceutical Co. Ltd.
Maruishi Pharmaceutical Co. Ltd. investment in Corporate Round - Kringle Pharma
Ogaki Kyoritsu Bank
Ogaki Kyoritsu Bank investment in Venture Round - Kringle Pharma
Resona Capital
Resona Capital investment in Venture Round - Kringle Pharma
Osaka University Venture Capital
Osaka University Venture Capital investment in Venture Round - Kringle Pharma
Miraca Holdings
Miraca Holdings investment in Venture Round - Kringle Pharma
Chishima Real Estate
Chishima Real Estate investment in Venture Round - Kringle Pharma
Yitu Capital
Yitu Capital investment in Venture Round - Kringle Pharma
Nanto Bank
Nanto Bank investment in Venture Round - Kringle Pharma
Venture Labo Investment
Venture Labo Investment investment in Venture Round - Kringle Pharma
HT Capital
HT Capital investment in Venture Round - Kringle Pharma
Official Site Inspections
http://www.kringle-pharma.com Semrush global rank: 5.35 M Semrush visits lastest month: 1.56 K
- Host name: www5212.sakura.ne.jp
- IP address: 133.167.8.152
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo
More informations about "Kringle Pharma"
Company Overview & History | Company | Kringle Pharma, Inc.
Dec 21, 2001 Company Overview Name Kringle Pharma , Inc. Established December 21, 2001 Representative President & CEO Kiichi Adachi Head Office 207 Saito Bio Incubator 7-7-15 …See details»
Kringle Pharma - Crunchbase Company Profile & Funding
Kringle Pharma, Inc., a biopharmaceutical company, develops pharmaceutical products based on its research on hepatocyte growth factor (HGF) and NK4. …See details»
Company | Kringle Pharma, Inc.
Kringle Pharma's code of conduct: We are always aware that we are performing important work that supports people’s health, and we take pride and responsibility for our actions. We …See details»
Kringle Pharma - Org Chart, Teams, Culture & Jobs - The Org
View Kringle Pharma's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Kringle Pharma Inc. - life-sciences-asia.com
Dec 21, 2001 Sun Pharma to Acquire Checkpoint Therapeutics; Valo Therapeutics Raises €19m Investment Round; Trimtech Therapeutics Raises £25m Seed Round for TPD; ...See details»
Organization | Kringle Pharma, Inc.
Kringle Pharma, Inc. Report issue. For profit Phase 2 Phase 3. Founded: Toyonaka Japan (2001 ...See details»
Kringle Pharma (TYO:4884) Company Profile & Description - Stock …
5 days ago Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The …See details»
Kringle Pharma, Inc. - Shared Research
Kringle Pharma, Inc. is a late clinical-stage biopharmaceutical company. It was founded as a biotech startup in Osaka in December 2001, and traces its roots back to Osaka University. …See details»
Kringle Pharma Company Profile | Management and Employees …
Kringle Pharma, Inc., a company that develops pharmaceutical products based on Hepatocyte Growth Factor (HGF), was approved to be listed on Tokyo Stock Exchange Mothers on …See details»
Kringle Pharma - Company Profile - Tracxn
Feb 28, 2025 Kringle Pharma rings up new fundingGlobal Corporate Venturing • Apr 08, 2020 • Kringle Pharma, Chishima Real Estate, Miraca Holdings, Nanto Bank and 2 others Global …See details»
IR Information | Kringle Pharma, Inc.
Kringle Pharma, Inc 207 Saito Bio Incubator 7-7-15 Saitoasagi, Ibaraki, OSAKA 567-0085, JAPASee details»
Kringle Pharma - Funding, Financials, Valuation & Investors
Kringle Pharma is registered under the ticker TYO:4884 . Stock Symbol TYO:4884 ; IPO Date Dec 28, 2020; Stock chart by . Investors. Edit Investors Section. Number of Lead Investors 5. …See details»
KRINGLE PHARMA, INC. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for KRINGLE PHARMA, INC. of IBARAKI, OSAKA. Get the latest business insights from Dun & Bradstreet.See details»
Kringle Pharma - Products, Competitors, Financials, Employees ...
Jul 7, 2015 Kringle Pharma primarily serves sectors that require advanced treatments for rare and difficult-to-treat diseases. It was founded in 2001 and is based in Osaka, Japan. …See details»
Kringle Pharma - Craft
Kringle Pharma is a clinical-stage biopharmaceutical company that focuses on the research and development of regenerative medicines. It offers protein drug substance products for the …See details»
Our Business | Company | Kringle Pharma, Inc.
Kringle Pharma was established as a university spin-off bio-venture dedicated to the R&D of therapeutic agents for intractable diseases, which refers to rare diseases that have unknown …See details»
Kringle Pharma, Inc. - Drug pipelines, Patents, Clinical trials
It is currently in Phase III and is produced by Kringle Pharma. Research and Development Phase III NCT04475224: In July 2020, Kringle Pharma initiated A Non-randomized, Multicenter, and …See details»
Kringle Pharma - Contacts, Employees, Board Members
Kringle Pharma has 5 current employee profiles, including Chief Scientific Officer and Director Kunio Matsumoto. Contacts. Edit Contacts Section. We're working on getting contact data for …See details»
Kringle Pharma 2025 Company Profile: Stock Performance
What is Kringle Pharma’s annual earnings per share (EPS)? Kringle Pharma’s EPS for 12 months was -$0.79. Data Transparency. Meet our data hygiene team. Discover how our experts …See details»
Learn about Kringle Pharma | Kringle Pharma, Inc.
Kringle Pharma is a biopharmaceutical company founded as a biotech startup based on the research findings at Osaka University and Keio University. We are the only company in the …See details»